Skip to main content

Advertisement

SpringerLink
Log in

Is rs8099917 Polymorphism of IL-28B Gene a Good Predictor of Response to Therapy of HCV than rs12979860? An Egyptian Study

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Hepatitis C virus (HCV) infection is the major etiology of chronic liver disease. Polymorphisms in the IL-28B gene region are important in predicting outcome following therapy for chronic hepatitis C virus infection. The aim of this study was to detect the relationship between IL-28B polymorphism and responses to therapy in patients infected with genotype 4. This study included one hundred chronic hepatitis C patients infected with genotype 4, received PEG-IFNα2b plus ribavirin for 24 weeks, as well as, 20 healthy subjects serving as control. Clinical and laboratory parameters, including genetic variation near the IL-28B gene (rs8099917 and rs12979860), were assessed. The results of this study showed significant difference between responders and non-responders as regard SNPs in the interleukin 28B gene at rs8099917 and rs12979860. In rs8099917, TT genotypes had more frequency in responders than GG genotypes. On the other hand, CC genotype in rs12979860 had more frequency in responders than TT genotype. By multiple regression analysis, rs8099917 (TT), total bilirubin, and prothrombin time were independent factors affecting the response to treatment. This results demonstrate that in HCV genotype 4-infected patients, rs12979860 (CC) and rs8099917 (TT) genotypes may identify patients who are likely to respond to treatment. IL-28B SNPs are good predictors of response to combination therapy of HCV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Shepard, C. W., Finelli, L., & Alter, M. J. (2005). Global epidemiology of hepatitis C virus infection. The Lancet Infectious Diseases, 5, 558–567.

    Article  PubMed  Google Scholar 

  2. Jou, J. H., & Muir, A. J. (2008). In the clinic. Hepatitis C. Annals of Internal Medicine, 148, 1–16.

    Article  Google Scholar 

  3. Kamal, S. M., & Naser, L. A. (2008). Hepatitis C genotype4: what we know what we don’t yet know. Hepatology, 47, 1371–1383.

    Article  CAS  PubMed  Google Scholar 

  4. Fried, M. W., Shiffman, M. L., & Reddy, K. R. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347(13), 975–982.

    Article  CAS  PubMed  Google Scholar 

  5. Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004). American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology, 39(4), 1147–1171.

    Article  PubMed  Google Scholar 

  6. Rehermann, B., & Nascimbeni, M. (2005). Immunology of hepatitis B virus and hepatitis C virus infection. Nature Reviews Immunology, 5, 215–229.

    Article  CAS  PubMed  Google Scholar 

  7. Pestka, S., Krause, C. D., & Walter, M. R. (2004). Interferons, interferon-like cytokines, and their receptors. Immunological Reviews, 202, 8–32.

    Article  CAS  PubMed  Google Scholar 

  8. Rauch, A., Kutalik, Z., & Descombes, P. (2010). Genetic variation in IL28B isassociated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 138, 1338–1348.

    Article  CAS  PubMed  Google Scholar 

  9. Houldsworth, A., Metzner, M., Rossol, S., Shaw, S., Kaminiski, E., Demaine, A. C., et al. (2005). Polymorphism in the IL12B gene and outcome of HCV infection. Journal of Interferon and Cytokine Research, 25, 271–276.

    Article  CAS  PubMed  Google Scholar 

  10. Ge, D., Fellay, J., & Thompson, A. J. (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 461, 399–401.

    Article  CAS  PubMed  Google Scholar 

  11. Ishak, K., Baptista, A., & Bianchi, L. (1995). Histological grading and staging of chronic hepatitis. Journal of Hepatology, 22, 696–699.

    Article  CAS  PubMed  Google Scholar 

  12. Afdhal, N. H., McHutchison, J. G., Zeuzem, S., Mangia, A., Pawlotsky, J. M., Murray, J. S., et al. (2011). Hepatitis C pharmacogenetics. Hepatology, 53, 336–345.

    Article  PubMed  Google Scholar 

  13. Kurbanov, F., Abdel-Hamid, M., Latanich, R., Astemborski, J., Mohamed, M., Mikhail, N. M., et al. (2011). Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort. Journal of Infectious Diseases, 204(9), 1391–1394.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Shaker, O. G., & Sadik, N. A. (2012). Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy. Journal of Gastroenterology and Hepatology, 27(12), 1842–1849.

    Article  CAS  PubMed  Google Scholar 

  15. Khairy, M., Fouad, R., Mabrouk, M., El-Akel, W., Awad, A. B., Salama, R., et al. (2013). The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis. Hepatitis Monthly, 13(7), e10509.

    PubMed Central  PubMed  Google Scholar 

  16. Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009). American Association for the Study of Liver Diseases. Diagnosis, management and treatment of hepatitis C. Hepatology, 49(4), 1335–1374.

    Article  CAS  PubMed  Google Scholar 

  17. McHutchison, J. G., Lawitz, E. J., & Shiffman, M. L. (2009). Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitisC infection. New England Journal of Medicine, 361(6), 580–593.

    Article  CAS  PubMed  Google Scholar 

  18. Thomas, D. L., Thio, C. L., & Martin, M. P. (2009). Genetic variation in IL28B and to spontaneous clearance of hepatitis C virus. Nature, 461, 780–798.

    Article  Google Scholar 

  19. Marcello, T., Grakoui, A., Barba-Spaeth, G., Machlin, E. S., Kotenko, S. V., MacDonald, M. R., et al. (2006). Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology, 131, 1887–1898.

    Article  PubMed  Google Scholar 

  20. Dellgren, C., Gad, H. H., Hamming, O. J., Melchjorsen, J., & Hartmann, R. (2009). Human interferonlambda3 is a potent member of the type III interferon family. Genes and Immunity, 10, 125–131.

    Article  CAS  PubMed  Google Scholar 

  21. Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T. E., et al. (2003). IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature Immunology, 4, 63–68.

    Article  CAS  PubMed  Google Scholar 

  22. Fried, M. W., Hadziyannis, S. J., Shiffman, M., Messinger, D., & Zeuzem, S. (2011). Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. Journal of Hepatology, 55(1), 69–75.

    Article  PubMed  Google Scholar 

  23. Aparicio, E., Parera, M., Franco, S., Prez-Alvarez, N., & Tural, C. (2010). IL28B SNP rs8099917 is strongly Associated with pegylated interferon-a and ribavirin therapy treatment failure in HCV/HIV-1 Coinfected Patients. PLoS ONE, 5, e13771.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Grebely, J., Petoumenos, K., Hellard, M., Matthews, G. V., & Suppiah, V. (2010). Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology, 52, 216–224.

    Article  Google Scholar 

  25. Stättermayer, A. F., Stauber, R., Hofer, H., Rutter, K., & Beinhardt, S. (2011). Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-naive Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 9(4), 344–350.

    Article  PubMed  Google Scholar 

  26. Yu, M., Huang, C., Huang, J., Chang, N., Yang, J., Lin, Z., et al. (2011). Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology, 53(1), 7–13.

    Article  CAS  PubMed  Google Scholar 

  27. Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., & Abate, M. L. (2009). IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics, 41, 1100–1104.

    Article  CAS  PubMed  Google Scholar 

  28. Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., & Sakamoto, N. (2009). Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic Hepatitis C. Nature Genetics, 41, 1105–1109.

    Article  CAS  PubMed  Google Scholar 

  29. Wang, T. S., Mo, L. R., Lim, R. T., Kuo, J. J., Chang, K. K., & Wu, J. J. (2008). Artificial neutral net work model is superior to logistic regression model in predicting treatment outcomes of interferon-combination of therapy in patient of chronic hepatitis C. Intervirology, 51, 14–20.

    Article  CAS  PubMed  Google Scholar 

  30. Hosogaya, S., Ozaki, Y., Enomoto, N., & Akahine, Y. (2006). Analysis of prognostic factors in therapeutic responses to interferon in patients with CHC. Translational Research, 148, 79–86.

    Article  CAS  PubMed  Google Scholar 

  31. Gad, R. R., Males, S., El Makhzandy, H., Showman, S., Hassan, A., & Atallah, N. (2008). Predictors of sustained virological response in patients infected with hepatitis C virus genotype4. Liver International, 28, 1112–1119.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Egyptian Science and Technology Development Fund (Project number 1512 to PI; Olfat Shaker).

Conflict of interest

The authors have declared that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Giza, Egypt

    Olfat Shaker & Amal Rashad

  2. Medical Biochemistry, Faculty of Medicine, Beni Sueif University, Beni Suef, Egypt

    Ghada Abd El Aziz

  3. Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Giza, Egypt

    Maissa El Raziky

Authors
  1. Olfat Shaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amal Rashad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ghada Abd El Aziz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maissa El Raziky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olfat Shaker.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shaker, O., Rashad, A., Aziz, G.A.E. et al. Is rs8099917 Polymorphism of IL-28B Gene a Good Predictor of Response to Therapy of HCV than rs12979860? An Egyptian Study. Cell Biochem Biophys 71, 307–314 (2015). https://doi.org/10.1007/s12013-014-0199-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-0199-7

Keywords

Search

Navigation